Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02347345 · ClinicalTrials.gov registry record · Phase 4
Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs
A Phase 4 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT02347345 is a Phase 4 study that has completed, run by Rockefeller University. The registered enrollment target is 34 participants.
The verdict
NCT02347345, a Phase 4 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
The investigator's hypothesis is that active injectors will show a partial reduction in markers of immune activation with HCV therapy whereas non-injectors will show a more significant reduction in these markers, and will exhibit levels of immune activation that approach that seen in similarly studied healthy volunteers.This is based on observations that this group of investigators have made. They have shown that individuals who inject drugs have high level of immune activation in blood and tissue. Immune activation or chronic inflammation has been associated with accelerated aging, cardiovascular, renal and liver disease as well as CNS dysfunction. It remains unclear whether increased levels of immune activation are due to non-sterile injection of drugs, chronic infection with Hepatitis C, chronic opiate use, or perhaps combinations of all 3. To understand the potential contribution of infection with Hepatitis C the investigators will compare levels of immune activation pre- and post treatment with an all oral, one pill once daily, interferon sparing treatment of HCV in 2 groups of chronically HCV infected patients- one actively injecting with drugs and the other free of injection for at least 4 months. Immune activation comparisons will also include non-injecting healthy volunteers.
Interventions
- DRUG Harvoni (Fixed dose combination ledipasvir/sofosbuvir)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-11-15 |
| Est. Completion | 2016-11-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02347345
The ClinicalTrials.gov registry entry for NCT02347345 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Harvoni (Fixed dose combination ledipasvir/sofosbuvir) is the first listed.
NCT02347345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02347345 about?
NCT02347345 is a clinical study titled "Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs". The investigator's hypothesis is that active injectors will show a partial reduction in markers of immune activation with HCV therapy whereas non-injectors will show a more significant reduction in these markers, and will exhibit levels of immune activation that approach that seen in similarly studi...
What is the current status of trial NCT02347345?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2016-11-15. Estimated completion is 2016-11-15.
What interventions are being tested in trial NCT02347345?
The interventions under investigation include: Harvoni (Fixed dose combination ledipasvir/sofosbuvir) (DRUG).
Who is sponsoring clinical trial NCT02347345?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.